Pemetrexed Diacid Crystal Forms for Mild, High-Yield Crystallization

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing crystalline forms of pemetrexed diacid face issues such as solvent residue control, high drying temperatures leading to degradation, lengthy crystallization periods, and operational difficulties in large-scale production, resulting in low yields and inefficiencies.

Innovation Solution

Development of novel crystalline forms (Form 1 and Form 2) of pemetrexed diacid characterized by specific PXRD patterns and TGA profiles, prepared under mild conditions using controlled pH adjustments and solvent mixtures, enabling high yields and stability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If solvents with higher boiling points are used in crystalline forms (C, D, E), then the crystallization process is facilitated, but solvent residue control becomes more difficult and requires increased burden during drug product preparation

Engineering Contradiction:
Improvecrystallization processVSAvoidsolvent residue control
Core Design Contradiction:
Ease of manufactureVSManufacturing precision

Solution Approach 1:

The patent changes the physical-chemical parameters of the solvent system by selecting isopropanol (boiling point 82.6°C) instead of high-boiling solvents like DMSO or DMF. This parameter change facilitates both crystallization and subsequent solvent removal, resolving the contradiction between ease of manufacture and manufacturing precision regarding solvent residue control.

Inventive Principle:
Principle #35Parameter changes

2Quantity of substance

If very high temperature (160-200°C) is applied in drying step for anhydrous crystalline forms (F, G), then complete drying is achieved, but pemetrexed diacid degradation risk increases

Engineering Contradiction:
Improvedrying completenessVSAvoidpemetrexed diacid stability
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent changes the drying temperature parameter from very high temperature (160-200°C) to moderate temperature (40-60°C) by using a crystalline form that incorporates water in its structure. This parameter change allows complete drying without degradation, resolving the contradiction between drying completeness and drug stability.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite crystalline structure (crystalline form A) that incorporates water molecules into the crystal lattice. This composite structure allows the material to be dried at lower temperatures while still achieving complete solvent removal, resolving the contradiction between drying completeness and stability.

Inventive Principle:
Principle #40Composite materials

3Ease of manufacture

If crystalline form A is used, then the crystallization process is simplified, but filtration becomes difficult resulting in time-consuming operation and low yield

Engineering Contradiction:
Improvecrystallization processVSAvoidfiltration efficiency and yield
Core Design Contradiction:
Ease of manufactureVSProductivity

Solution Approach 1:

The patent modifies the local quality of the crystalline structure by changing the solvent system to isopropanol, which produces crystals with different morphological properties. This local change in crystal structure improves filtration characteristics while maintaining the simplified crystallization process, resolving the contradiction between ease of manufacture and productivity.

Inventive Principle:
Principle #3Local quality

4Ease of manufacture

If crystalline form B is used, then the crystallization process is simplified, but the crystallization period becomes very long (up to 18 hours) reducing efficiency

Engineering Contradiction:
Improvecrystallization processVSAvoidcrystallization time
Core Design Contradiction:
Ease of manufactureVSLoss of time

Solution Approach 1:

The patent changes the solvent parameter from water or ethanol to isopropanol, which significantly reduces the crystallization time from up to 18 hours to approximately 2-4 hours while maintaining the simplicity of the crystallization process. This parameter change resolves the contradiction between ease of manufacture and time efficiency.

Inventive Principle:
Principle #35Parameter changes

5Ease of manufacture

If pH adjustment and heating are used to promote dissolution, then dissolution is enhanced, but unwanted discoloration develops requiring additional color treatment steps

Engineering Contradiction:
Improvedissolution processVSAvoidprocess steps
Core Design Contradiction:
Ease of manufactureVSDevice complexity

Solution Approach 1:

The patent changes the temperature parameter from high temperature (40°C to near boiling point) to low temperature (15-25°C) by using isopropanol as the solvent. This parameter change allows effective dissolution without thermal degradation that causes discoloration, thereby eliminating the need for additional color treatment steps and resolving the contradiction between ease of manufacture and process complexity.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The novel crystalline forms are stable, easily prepared on a large scale with high yields (>90%), and free from inter-conversion issues, overcoming the shortcomings of previous forms.

Implementation Method 1

dissolving pemetrexed disodium in a mixture of water and isopropanol to form a solution

Methodology Applied
Scientific EffectDissolution: Solvation

Implementation Method 2

adjusting the pH value of the solution to about 2.5 to 3.5 with an acid

Methodology Applied
Scientific EffectpH adjustment:

Implementation Method 3

isolating the precipitate

Methodology Applied
Scientific EffectPrecipitation: Precipitation

Implementation Method 4

crystallizing pemetrexed diacid by the following steps

Methodology Applied
Scientific EffectCrystallization: Crystallisation

Data Source

PatentEP3212193B1Crystalline forms of pemetrexed diacid and manufacturing processes therefor
Publication Date: 2026.04.15 SCINOPHARM TAIWAN LTD
  • EP3212193B1 patent drawingFigure 1
  • EP3212193B1 patent drawingFigure 2
  • EP3212193B1 patent drawing

AI summary

Crystalline forms of pemetrexed diacid are provided (Forms 1 and 2) which are readily produced for either laboratory-scale or industrial scale. Processes for the preparation of Forms 1 and 2 are also provided.